{
    "root": "ff42c38f-a772-4170-ac57-2213b45e887d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate",
    "value": "20250317",
    "ingredients": [
        {
            "name": "AMPHETAMINE SULFATE",
            "code": "6DPV8NK46S"
        },
        {
            "name": "AMPHETAMINE ASPARTATE MONOHYDRATE",
            "code": "O1ZPV620O4"
        },
        {
            "name": "DEXTROAMPHETAMINE SULFATE",
            "code": "JJ768O327N"
        },
        {
            "name": "DEXTROAMPHETAMINE SACCHARATE",
            "code": "G83415V073"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "GLYCERYL MONOSTEARATE",
            "code": "230OU9XXE4"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsules , cns stimulant , indicated treatment attention deficit hyperactivity disorder ( adhd ) . ( 1 ) • children ( ages 6-12 ) : efficacy established one 3-week outpatient , controlled trial one analogue classroom , controlled trial children adhd . ( 14 ) • adolescents ( ages 13-17 ) : efficacy established one 4-week controlled trial adolescents adhd . ( 14 ) • adults : efficacy established one 4-week controlled trial adults adhd . ( 14 )",
    "contraindications": "• pediatric patients ( ages 6-17 ) : 10 mg daily morning . maximum dose children 6-12 years age 30 mg daily . ( 2.2 , 2.3 , 2.4 ) • adults : 20 mg daily morning . ( 2.5 ) • pediatric patients ( ages 6-17 ) severe renal impairment : 5 mg daily morning . maximum dose children 6- 12 years age severe renal impairment 20 mg daily . ( 2.6 , 8.6 ) • adults severe renal impairment : 15 mg daily morning . ( 2.6 , 8.6 ) • patients esrd : recommended . ( 2.6 , 8.6 )",
    "warningsAndPrecautions": "dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsules 20 mg hard gelatin capsules , pink opaque cap body , printed “ amg ” cap “ 280 ” body , supplied follows : bottles 100 ndc 63629-1975-1 dispense tight , light-resistant container defined usp . store room temperature , 20°c 25°c ( 68°f 77°f ) . [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsule contraindicated patients following conditions : •advanced arteriosclerosis •symptomatic cardiovascular disease •moderate severe hypertension •hyperthyroidism •in patients known hypersensitive amphetamine , components dextroamphetamine saccharate , amphetamine aspartate monohydrate , dextroamphetamine sulfate , amphetamine sulfate extended-release capsules . hypersensitivity angioedema anaphylactic reported patients treated amphetamine products [ ( 6.2 ) ] •glaucoma •agitated states •history abuse •patients taking monoamine oxidase inhibitors ( maois ) , within 14 days stopping maois ( including maois linezolid intravenous methylene blue ) , increased risk hypertensive crisis [ ( 5.6 ) ( 7.1 ) ]",
    "indications_original": "Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, a CNS stimulant, are indicated for the treatment of attention deficit hyperactivity disorder (ADHD). ( 1 ) • Children (ages 6-12): Efficacy was established in one 3-week outpatient, controlled trial and one analogue classroom, controlled trial in children with ADHD. ( 14 ) • Adolescents (ages 13-17): Efficacy was established in one 4-week controlled trial in adolescents with ADHD. ( 14 ) • Adults: Efficacy was established in one 4-week controlled trial in adults with ADHD. ( 14 )",
    "contraindications_original": "• Pediatric patients (ages 6-17): 10 mg once daily in the morning. Maximum dose for children 6-12 years of age is 30 mg once daily. ( 2.2 , 2.3 , 2.4 ) • Adults: 20 mg once daily in the morning. ( 2.5 ) • Pediatric patients (ages 6-17) with severe renal impairment: 5 mg once daily in the morning. Maximum dose for children 6- 12 years of age with severe renal impairment is 20 mg once daily. ( 2.6 , 8.6 ) • Adults with severe renal impairment: 15 mg once daily in the morning. ( 2.6 , 8.6 ) • Patients with ESRD: not recommended. ( 2.6 , 8.6 )",
    "warningsAndPrecautions_original": "Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules 20 mg are hard gelatin capsules, pink opaque cap and body, printed “AMG” on cap and “280” on body, which are supplied as follows:\n                  \n                     Bottles of 100 NDC 63629-1975-1\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  Store at room temperature, 20°C to 25°C (68°F to 77°F). [see USP CONTROLLED ROOM TEMPERATURE].\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule administration is contraindicated in patients with the following conditions:\n                  \n                     \n                        •Advanced arteriosclerosis\n                     \n                        •Symptomatic cardiovascular disease \n                     \n                        •Moderate to severe hypertension \n                     \n                        •Hyperthyroidism \n                     \n                        •In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions (6.2)]\n                     \n                     \n                        •Glaucoma \n                     \n                        •Agitated states \n                     \n                        •History of drug abuse \n                     \n                        •Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.6) and Drug Interactions (7.1)]"
}